Royalty Pharma (RPRX) Return on Capital Employed (2020 - 2026)
Royalty Pharma (RPRX) posted Return on Capital Employed of 8.28% for Q1 2026, little changed sequentially from 8.27% in Q4 2025, and down 308.0% YoY from 3.98% in Q1 2025.
Royalty Pharma (RPRX) Return on Capital Employed (2020 - 2026) Analysis & Trends
Royalty Pharma has reported Return on Capital Employed for 7 years, with the latest figure at 8.28% in Q1 2026.
- Quarterly Return on Capital Employed fell 308.0% year-over-year to 8.28% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 8.28% (down 308.0% YoY) and the FY2025 annual result came in at 8.53%, up 48.0% from the prior year.
- Return on Capital Employed steadied at 8.28% in Q1 2026 per RPRX's latest filing, from 8.27% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 11.36% in Q1 2025 and troughed at 1.91% in Q4 2022.
- A 5-year average of 6.81% and a median of 7.66% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2023: Return on Capital Employed tumbled 629 bps in 2022, then soared 744 bps in 2023.
- Over 5 years, Return on Capital Employed stood at 1.91% in 2022, then surged by 390 bps to 9.35% in 2023, then retreated by 18 bps to 7.66% in 2024, then climbed by 8 bps to 8.27% in 2025, then gained by 0 bps to 8.28% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 8.28%, 8.27%, and 8.37% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -36.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.88% |
| Mar 31, 2026 | 8.28% |
| Dec 31, 2025 | 8.27% |
| Sep 30, 2025 | 8.37% |
| Jun 30, 2025 | 10.98% |
| Mar 31, 2025 | 11.36% |
| Dec 31, 2024 | 7.66% |
| Sep 30, 2024 | 9.25% |
| Jun 30, 2024 | 5.78% |
| Mar 31, 2024 | 5.82% |
| Dec 31, 2023 | 9.35% |
| Sep 30, 2023 | 2.42% |
| Jun 30, 2023 | 2.75% |
| Mar 31, 2023 | 3.58% |
| Dec 31, 2022 | 1.91% |
| Sep 30, 2022 | 5.69% |
| Jun 30, 2022 | 6.07% |
| Mar 31, 2022 | 8.21% |
| Dec 31, 2021 | 8.20% |
| Sep 30, 2021 | 9.43% |